Cytomodulating peptides and methods for treating neurological disorders

• US 20040186052A1
• Filed: 10/24/2003
• Published: 09/23/2004
• Est. Priority Date: 10/24/2002
• Status: Abandoned Application

• Current Assignee: SangStat Medical Corporation (Sanofi )
• Original Assignee: SangStat Medical Corporation (Sanofi )
• Inventors: Lazarov, Mirella Emilova, Buelow, Roland, Fong, Timothy, Iyer, Suhasini
• Application Number:
  US10/693,331
• Publication Number:
  US 20040186052A1
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/1774 Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Compositions and methods are provided for inhibiting neuronal cell death and the loss of neuronal contacts resulting from acute and chronic neurological disorders, including neurodegenerative and neuroinflammatory diseases. The subject compositions and methods utilize RDP-58 compositions capable of providing a direct neuroprotective effect on neuronal cells in conjunction with the inhibition of autoimmune and inflammatory processes.

Claims

13. A method for inhibiting neural cell death, comprising contacting at least one neural cell with a neuroprotective amount of an RDP-58 composition.

14. The method according to claim 13, wherein said neural cell is a neuronal cell.

15. The method according to claim 13, wherein said neural cell is a glial cell.

16. The method according to claim 13, wherein said contacting occurs in vitro.

17. The method according to claim 13, wherein said contacting occurs in vivo.

18. The method according to claim 13, wherein said contacting occurs ex vivo.

19. A method for reducing neural cell death in a patient suffering from a neurological disorder, comprising administering to said patient a neuroprotective amount of an RDP58 composition.

20. A method for reducing neural cell death and inflammation in a patient suffering from a neurological disorder, comprising administering to said patient a neuroprotective amount of an RDP-58 composition.

21. A pharmaceutical composition useful for the treatment of a neurological disorder, comprising an RDP-58 composition.

1. A method for treating a neurological disorder, comprising administering to a patient suffering from said neurological disorder a therapeutically effective amount of an RDP-58 composition.

2. The method according to claim 1, wherein said neurological disorder is an acute neurological disorder.

3. The method according to claim 2, wherein said acute disorder involves inflammation.

4. The method according to claim 3, wherein said acute disorder involving inflammation is selected from the group consisting of hemorrhagic stroke, ischemic stroke, traumatic brain injury, traumatic spinal cord injury, and traumatic peripheral nerve injury.

5. The method according to claim 1, wherein said neurological disorder is a chronic disorder.

6. The method according to claim 5, wherein said chronic disorder involves inflammation.

7. The method according to claim 6, wherein said chronic disorder involving inflammation is a neuromuscular disorder.

8. The method according to claim 7, wherein said neuromuscular disorder is myasthenia gravis.

9. The method according to claim 6, wherein said chronic disorder involving inflammation is HIV-associated dementia.

10. The method according to claim 6, wherein said chronic disorder involving inflammation is a demyelinating disease.

11. The method according to claim 10, wherein said demyelinating disease is selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, optic neuromyelitis, transverse myelopathy, chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barre syndrome.

12. The method according to claim 6, wherein said chronic disorder involving inflammation is chronic fatigue syndrome.

22. The pharmaceutical composition according to claim 21, additionally comprising an agent that is a JNK or p38 inhibitor other than an RDP-58 peptide, a TCR peptide, or an HLA peptide.

23. The pharmaceutical composition according to claim 22, wherein said agent is selected from the group consisting of minocycline, VX-608, SB203580, CEP-1347, SB-202190 and PD169316.

24. The pharmaceutical composition according to claim 23, wherein the neurotrophic factor is selected from the group consisting of GDNF, BDNF, NGF, CNTF, IGF and LIF.

23-1. The pharmaceutical composition according to claim 21, additionally comprising a neurotrophic factor.

25. A method for increasing the survival of a cell transplanted into a patient for the treatment of a neurological disorder, comprising administering to said patient a neuroprotective amount of an RDP-58 composition.

26. The method according to claim 25, wherein said cell is a neural stem cell.

27. The method according to claim 25, wherein said cell is a fetal cell.

28. The method according to claim 25, wherein said cell is a neuron.

29. The method according to claim 28, wherein said neuron is a dopaminergic neuron or a cholinergic neuron.

30. The method according to claim 25, further comprising contacting said cell with said RDP-58 composition prior to transplanting the cell.